To Assess Compliance With a Once-daily Regimen of Lamivudine, Efavirenz and Didanosine

NCT00207168 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

120

Enrollment

INDUSTRY

Sponsor class

Conditions

AIDS

Interventions

BEHAVIORAL: Compliance

Sponsor

Bristol-Myers Squibb

Collaborators

[object Object]
[object Object]